Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

FAYETTEVILLE, NY, UNITED STATES, January 7, 2026 /EINPresswire.com/ — January is traditionally a peak period for pharmaceutical list price adjustments. The AnalySource team analyzed Wholesale ...

Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, announced that it ...

Bayer has opened a new legal front in the long-running battles over COVID-19 vaccine technology, suing several major ...

Bayer's agrochemicals unit Monsanto has filed lawsuits in the US against the manufacturers of mRNA-based COVID-19 vaccines, ...

Five sensational income stocks -- sporting yields ranging from 5.3% to 13.1% -- can fatten investors' pocketbooks in the new ...

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in. Pfizer Inc. (NYSE:PFE) is among ...

Initiatives from former President Joe Biden and current President Donald Trump have been effective in reducing the prices of ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications, even as the Trump administration pressures them for ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Drugmakers hike prices 350 drugs in January, including Pfizer's COVID-19 vaccine and hospital drugs, with a median increase of 4%.